Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30, 2023 MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update. “We continue to make good progress towards the closing of o
Revenue of $159.8 million 1.6% higher than second quarter 2022 excluding MakerBot
Highest-ever recurring revenue in Consumables and Customer Service
GAAP net loss of $38.6 million, or $0.56.
On July 19, 2023, the Federal Trade Commission (FTC) and the Antitrust Division of the Department of Justice (DOJ) (collectively, the "Agencies") issued a draft update of the Merger Guidelines.
When losing, some players seek to change the rules. Others seek to change the playing field. On July 19, 2023, the U.S. Department of Justice and the Federal Trade Commission.